Marius Bill

Dr. Marius Bill

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MBMarius Bill
Marius Bill
KMKrzysztof Mrózek
Krzysztof Mrózek
JKJessica Kohlschmidt
Jessica Kohlschmidt
AEAnn-Kathrin Eisfeld
Ann-Kathrin Eisfeld
CWChristopher J. Walker
Christopher J. Walker
CBClara D. Bloomfield
Clara D. Bloomfield
Significance: Balanced rearrangements involving 11q23/ KMT2A are among the most frequent chromosomal abnormalities in acute myeloid leukemia (AML). We analyzed the mutational status of 81 genes, clinical features and outcomes of patients with recurring 11q23/ KMT2A rearrangements. We found that mutations in genes of the RAS pathway were most frequent, and that there were differences in mutation patterns among patients with different 11q23/ KMT2A rearrangements. Outcomes of patients age <60 y with t(9;11)(p22;q23)/ KMT2A - MLLT3 , currently classified in the intermediate-risk group of the 2017 European LeukemiaNet classification, were superior to outcomes of intermediate-risk patients without t(9;11). Older patients with t(9;11) and patients with other 11q23/ KMT2A rearrangements had poor outcomes. Our study improves understanding of the mutational landscape and clinical implications for AML patients with 11q23/ KMT2A rearrangements.

3 February 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
MBMarius Bill
Marius Bill
MJMadlen Jentzsch
Madlen Jentzsch
LBLara Bischof
Lara Bischof
JKJessica Kohlschmidt
Jessica Kohlschmidt
JGJuliane Grimm
Juliane Grimm
SSSebastian Schwind
Sebastian Schwind
Somatic mutations in the isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are common in acute myeloid leukemia (AML). The prognostic impact of the presence of IDH mutations may be influenced by the comutational status, the specific location of the mutation (ie, IDH1 R132, IDH2 R140, and IDH2 R172) at diagnosis, and the dynamics of the mutation burden during disease course. Even though many patients with IDH-mutated AML are consolidated by hematopoietic stem cell transplantation (HSCT), the underlying biology and prognostic consequences remain largely unknown. Here, we present a large analysis of 292 patients with AML who received HSCT in complete remission (CR) or CR with incomplete peripheral recovery (CRi), in which we assessed the IDH mutation status at diagnosis and HSCT as a potential marker for measurable residual disease (MRD). About a quarter of all patients were IDH-mutated at diagnosis. The diagnostic presence of IDH mutations in AML did not have a significant prognostic impact when consolidated with HSCT. However, IDH1 R132 and IDH2 R172 MRD positivity in remission at HSCT associated with an increased risk of relapse, while IDH2 R140 mutations did not. The IDH2 R140 variant allele frequency (VAF) at diagnosis was higher, clustering around 50%, and the mutation clearance at HSCT in morphologic remission was much lower compared with IDH1 R132 and IDH2 R172. In our cohort, IDH2 R140 mutations behaved more like a clonal hematopoiesis-related aberration, while IDH1 R132 and IDH2 R172 harbored AML disease-specific features.

17 June 2026 in Nature
Verified
Journal Article
Open access
DFDyke Ferber
Dyke Ferber
LHLars Hilgers
Lars Hilgers
CHChristiane Höper
Christiane Höper
BKBenedict Kinny-Köster
Benedict Kinny-Köster
JEJan-Niklas Eckardt
Jan-Niklas Eckardt
JKJakob Nikolas Kather
Jakob Nikolas Kather
Large language models (LLMs) show great potential for clinical decision-making, yet most applications remain narrow, task-specific chat tools rather than systems integrated into clinical workflows 1,2 . However, building physician copilots will require models that operate within the electronic health record (EHR), with governed access to patient data and the ability to initiate permitted EHR actions within defined safety constraints. Yet it remains unproven whether such a system can manage patient cases with physician-level performance. Here we show that MIRA (Medical Intelligence for Reasoning and Action), an autonomous artificial intelligence agent operating in a sandboxed EHR environment, can navigate a large clinical action space to obtain patient histories; order and interpret laboratory, imaging and microbiology tests; generate differential diagnoses; and formulate treatment plans such as prescribing medications, scheduling surgical procedures and planning admissions. In simulations on real patient cases spanning multiple diagnoses, MIRA outperformed physicians in diagnostic accuracy and made guideline-concordant, medication-safe and appropriate admission decisions. Compared with previous LLM applications that addressed isolated subtasks or provided free-text advice, these results suggest that an EHR-integrated artificial intelligence agent can turn clinical intent into structured, actionable EHR operations, possibly making it a more effective decision-support partner for physicians. Further work is needed to establish generalization, safety and governance through prospective, real-world studies.

16 January 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
DPDimitrios Papaioannou
Dimitrios Papaioannou
SVStefano Volinia
Stefano Volinia
DNDeedra Nicolet
Deedra Nicolet
MŚMichał Świerniak
Michał Świerniak
APAndreas Petri
Andreas Petri
RGRamiro Garzon
Ramiro Garzon
Circular RNAs (circRNAs) are noncoding RNA molecules that display a perturbed arrangement of exons, called backsplicing. To examine the prognostic and biologic significance of circRNA expression in cytogenetically normal acute myeloid leukemia (CN-AML), we conducted whole-transcriptome profiling in 365 younger adults (age 18-60 years) with CN-AML. We applied a novel pipeline, called Massive Scan for circRNA, to identify and quantify circRNA expression. We validated the high sensitivity and specificity of our pipeline by performing RNase R treatment and RNA sequencing in samples of AML patients and cell lines. Unsupervised clustering analyses identified 3 distinct circRNA expression–based clusters with different frequencies of clinical and molecular features. After dividing our cohort into training and validation data sets, we identified 4 circRNAs (circCFLAR, circKLHL8, circSMC1A, and circFCHO2) that were prognostic in both data sets; high expression of each prognostic circRNA was associated with longer disease-free, overall, and event-free survival. In multivariable analyses, high circKLHL8 and high circFCHO2 expression were independently associated with better clinical outcome of CN-AML patients, after adjusting for other covariates. To examine the biologic relevance of circRNA expression, we performed knockdown screening experiments in a subset of prognostic and gene mutation–related candidate circRNAs. We identified circFBXW7, but not its linear messenger RNA, as a regulator of the proliferative capacity of AML blasts. In summary, our findings underscore the molecular associations, prognostic significance, and functional relevance of circRNA expression in CN-AML.

14 August 2019 in Haematologica
Verified
Journal Article
Open access
MBMarius Bill
Marius Bill
DNDeedra Nicolet
Deedra Nicolet
JKJessica Kohlschmidt
Jessica Kohlschmidt
CWChristopher J. Walker
Christopher J. Walker
KMKrzysztof Mrózek
Krzysztof Mrózek
CBClara D. Bloomfield
Clara D. Bloomfield
Leukemia stem cells (LSC) are more resistant to standard chemotherapy and their persistence during remission can cause relapse, which is still one of the major clinical challenges in the treatment of acute myeloid leukemia (AML). A better understanding of the mutational patterns and the prognostic impact of molecular markers associated with stemness could lead to better clinical management and improve patients' outcomes. We applied a previously described 17-gene expression score comprising genes differently expressed between LSC and leukemic bulk blasts, for 934 adult patients with de novo AML, and studied associations of the 17-gene LSC score with clinical data and mutation status of 81 genes recurrently mutated in cancer and leukemia. We found that patients with a high 17-gene score were older and had more mutations. The 17-gene score was found to have a prognostic impact in both younger (aged <60 years) and older (aged ≥60 years) patients with AML. We also analyzed the 17-gene LSC score in the context of the 2017 European LeukemiaNet genetic-risk classification and found that for younger patients the score refined the classification, and identified patients currently classified in the European LeukemiaNet Favorable-risk category who had a worse outcome.

8 March 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
CWChristopher J. Walker
Christopher J. Walker
KMKrzysztof Mrózek
Krzysztof Mrózek
HOHatice Gulcin Ozer
Hatice Gulcin Ozer
DNDeedra Nicolet
Deedra Nicolet
JKJessica Kohlschmidt
Jessica Kohlschmidt
CBClara D. Bloomfield
Clara D. Bloomfield
Although ∼80% of adult patients with cytogenetically normal acute myeloid leukemia (CN-AML) achieve a complete remission (CR), more than half of them relapse. Better identification of patients who are likely to relapse can help to inform clinical decisions. We performed RNA sequencing on pretreatment samples from 268 adults with de novo CN-AML who were younger than 60 years of age and achieved a CR after induction treatment with standard “7+3” chemotherapy. After filtering for genes whose expressions were associated with gene mutations known to impact outcome (ie, CEBPA, NPM1, and FLT3-internal tandem duplication [FLT3-ITD]), we identified a 10-gene signature that was strongly predictive of patient relapse (area under the receiver operating characteristics curve [AUC], 0.81). The signature consisted of 7 coding genes (GAS6, PSD3, PLCB4, DEXI, JMY, NRP1, C10orf55) and 3 long noncoding RNAs. In multivariable analysis, the 10-gene signature was strongly associated with relapse (P < .001), after adjustment for the FLT3-ITD, CEBPA, and NPM1 mutational status. Validation of the expression signature in an independent patient set from The Cancer Genome Atlas showed the signature’s strong predictive value, with AUC = 0.78. Implementation of the 10-gene signature into clinical prognostic stratification could be useful for identifying patients who are likely to relapse.